Review of treatment response in rheumatoid arthritis: assessment of heterogeneity

• Published in: Current medical research and opinion Vol. 27; no. 4; pp. 697 - 711
• Main Authors: Goetz, Iris, Carter, Gebra Cuyún, Lucero, Melanie, Zarotsky, Victoria, Alatorre, Carlos I., Cantrell, Ronald A., Paczkowski, Rosirene, Sterling, Kimberly L.
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01-04-2011; Taylor & Francis
• Subjects: Algorithms; Antirheumatic agents; Arthritis, Rheumatoid - classification; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - therapy; Biologic modifiers; Biomarkers - analysis; Drug therapy; Health Behavior; Humans; Individuality; Predictive Value of Tests; Predictors; Prognosis; Rheumatoid arthritis; Socioeconomic Factors; Treatment Outcome
• ISSN: 0300-7995; 1473-4877
• DOI: 10.1185/03007995.2010.549805

Abstract
Objective:
Rheumatoid arthritis (RA) is a chronic, systemic, progressive, inflammatory disorder. The primary goals of treatment in RA are to reduce the signs and symptoms of disease, prevent progression of joint damage and improve patients' physical function. Patients with different sociodemographic characteristics, varying degrees of severity of illness, and comorbidities tend to exhibit differential response to treatment. The purpose of this review was to identify a broad set of factors that are associated with and/or predictive of RA treatment response and determine those that warrant further research.
Research design and methods:
A comprehensive review of the literature from the last 10 years was performed using three key databases (PubMed, EMBASE, and Cochrane). All relevant articles that met the inclusion/exclusion criteria were selected and scored for their levels of evidence using the National Institute of Clinical Excellence (NICE) scoring method. Data on study design, interventions and treatment outcomes were abstracted using a structured abstraction table.
Results:
A total of 30 articles were included in the review and data abstraction. Besides gender, baseline clinical variables such as C-reactive protein level, erythrocyte sedimentation rate, measures of disease activity, and Health Assessment Questionnaire scores (based on five patient-centered dimensions) were consistently associated with treatment response over time.
Conclusions:
This comprehensive literature review identified several factors associated with treatment response which might be valuable to include as relevant measures in future studies of RA treatment. Inclusion of these factors, particularly those in the clinical and sociodemographic domains, in the design of future trials will further the understanding that ultimately may help clinicians deliver targeted treatment to community practice RA patients, thus resulting in improved patient outcomes.